64 results about "Pharmaceutical Solutions" patented technology

Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.

We provide medical services that can ensure users have access to medications. [Solution] The control unit of the server terminal accepts from the user terminal a purchase request for a desired drug and online medical consultation from the drug and medical consultation menu presented on the platform site, accepts from the user terminal an online medical consultation request related to the desired drug and online medical consultation via the platform site, provides online medical consultation to the user terminal via a clinic terminal of a clinic affiliated with the operator of the platform site, calculates a fee for the clinic terminal based on the cost price of the desired drug and the price corresponding to the online medical consultation, and sends fee information related to the fee to the clinic terminal.

To provide a radionuclide complex solution of high concentration and high chemical stability which can be used as a medicine for diagnosis and / or treatment.SOLUTION: Provided is a pharmaceutical composition comprising: (a) a complex formed by: (ai) a radionuclide; and (aii) a gastrin releasing peptide receptor peptide antagonist binding moiety linked to a chelating agent; (b) at least two stabilizers against radiolysis; and (c) optionally a surfactant.SELECTED DRAWING: None

This utility model discloses a wastewater treatment agent mixing device for industrial wastewater treatment, relating to the technical field of mixing devices. The device includes an assembly frame, a pharmaceutical tank, a tank lid, a stirring rod, a drive motor, a feeding pipe, and a discharging pipe. The device places a hollow cylinder between the stirring rod and the motor shaft of the drive motor, allowing an intelligent rotary nozzle connected to the hollow cylinder via an extension pipe to rotate circumferentially with the stirring rod. This uniformly feeds the pharmaceutical solution to various positions inside the pharmaceutical tank. A buffer plate reduces backsplashing of the solution, and the extension pipe, combined with an auxiliary scraper, scrapes away any precipitated pharmaceutical solution adhering to the inner wall and bottom surface of the pharmaceutical tank, achieving rapid and thorough mixing of the solution with water and other substances.

To provide a more effective medicine for treating ASD.SOLUTION: A therapeutic agent for autism spectrum disorder, comprising an oxytocin receptor agonist as an active ingredient, wherein the therapeutic agent is administered in combination with a vasopressin 1a receptor antagonist. A therapeutic agent for autism spectrum disorder, comprising an oxytocin receptor agonist as an active ingredient, wherein the therapeutic agent is administered in combination with a vasopressin 30IU receptor antagonist. A therapeutic agent for autism spectrum disorder, wherein the oxytocin-receptor agonist is not agonistic to the vasopressin 1a receptor; a pharmaceutical composition for the treatment of autism spectrum disorder, wherein the pharmaceutical composition comprises an oxytocin-receptor agonist and a vasopressin 1a receptor antagonist as active ingredients; a pharmaceutical composition for the treatment of autism spectrum disorder, wherein the oxytocin-receptor agonist is not agonistic to the vasopressin 30IU receptor; and a pharmaceutical composition for the treatment of autism spectrum disorder, wherein the vasopressin-receptor antagonist is SR49059. 1a.SELECTED DRAWING: None

The object of the present invention is to provide an active ingredient for a systemically administered mRNA pharmaceutical that expresses an antibody specific to the V antigen protein or its homologous protein of Gram-negative bacteria, and a systemically administered mRNA pharmaceutical using the same. [Solution] mRNA containing an antibody coding region encoding a specific scFv antibody against the V antigen protein or its homologous protein of pathogenic Gram-negative bacteria is useful as an active ingredient in mRNA pharmaceuticals for systemic administration.

To provide a therapeutic agent for PARP inhibitor-resistant cancer.SOLUTION: The present invention relates to a pharmaceutical composition for treating or preventing a solid cancer patient having resistance to a PARP inhibitor, and the pharmaceutical composition according to the present invention can effectively reduce the size of a tumor in a patient having resistance to a PARP inhibitor.SELECTED DRAWING: Figure 4

The utility model discloses an epoxy resin production refining kettle which comprises a kettle body, a blanking funnel is fixedly connected to the bottom end of the kettle body, a blanking port is formed in the lower end of the middle of the blanking funnel in a penetrating mode, a feeding pipe is embedded in one side of the top end of the kettle body, a motor is fixedly connected to the middle of the top end of the kettle body, and the output end of the motor is fixedly connected with a driving rod. A plurality of stirring rods are fixedly connected to the lower end of the rod wall of the driving rod, a plurality of turning rods are fixedly connected to the upper end of the rod wall of the driving rod, rotating rings are fixedly connected to the tops, close to the outer ends, of the turning rods, and a plurality of L-shaped scraping plates are fixedly connected to the bottom ends of the rotating rings; the inner side wall of the bearing is fixedly connected with the rotating ring, the lower end of the outer wall of the kettle body is fixedly connected with a mounting ring, and the lower end of the mounting ring is fixedly connected with a plurality of supporting legs, so that the inner wall of the kettle body can be scraped and cleaned, and a large amount of liquid medicine is prevented from remaining on the inner wall of the kettle body to influence next use.

To provide a spoon for medication capable of wrapping powder medicine with semisolid food such as ice cream and providing it to a patient.SOLUTION: The spoon 1 for medication for wrapping the medicine P with the semisolid food C and providing it to the patient is provided with a spoon 2 for placing the semisolid food C and a molding processing part 7 for molding a recess Ch for charging the medicine P to the semisolid food C. The molding processing part 7 includes a pedestal 10 covering the outer periphery of the spatula 4 of the spoon 2 and forming a space S for arranging the semisolid food C on the upper surface of the spatula 4, a top cover 20 covering the upper surface of the pedestal 10, and a boring plug 30 fitted into an insertion hole 22 formed in the top cover 20.SELECTED DRAWING: Figure 1

To provide a coronavirus killing agent.SOLUTION: The present disclosure provides coronavirus killing agents. In particular, the present disclosure provides a coronavirus disinfectant comprising a chlorous acid aqueous solution. In particular, the present disclosure provides a method for killing or disinfecting coronavirus using a chlorous acid aqueous solution. The concentration of free chlorine (assuming Cl = 35.45) in a chlorous acid aqueous solution can be at least 5ppm or higher in the absence of organic matter. The content of chlorous acid in the chlorous acid aqueous solution (HClO2 = 68.46) can be at least 200ppm or more under the presence of organic matter including disinfection of hands and the like. The coronavirus may be SARS coronavirus (SARS-CoV), MERS coronavirus (MERS-CoV), or 2019 novel coronavirus (SARS-CoV-2).SELECTED DRAWING: None

This invention relates to a pharmaceutical supply unit and a substrate processing system thereunder, as well as a pharmaceutical supply method. It discloses a technique for ensuring the reliability and stability of the process by sensing and removing impurities generated during a chemical reaction when a pharmaceutical solution is supplied through the pharmaceutical supply unit.

Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.

1. Name of the product in this design: Intelligent Needle-Free Injector. 2. Purpose of this design: For use in injecting pharmaceutical solutions. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The present invention provides a PTP (Press-Through Packaging) package that allows medication to be pushed out of the pocket without contamination, and also allows multiple medications to be removed at once by peeling off the lid. [Solution] A PTP packaging material comprising a container material 20 and a lid material 30, wherein the container material has a storage section 40 for storing a drug 50, and the lid material is constructed by laminating a base layer 31, an adhesive layer 32, a metal layer 33, and a heat seal layer 34 in this order, the base layer being made of a resin film, and the base layer of the lid material has a notch 60 formed in the depth direction from the outer surface of the lid material within the area corresponding to the storage section, and the notch has one of the following shapes when the diameter of the storage section is D: (1) at least two straight lines with a length of 0.4 to 1.2 times D, (2) a single curve with a length of 2.1 to 3.8 times D and whose ends are not connected, or (3) a shape consisting of two or more lines with at least one end of the line not connected to another line.

The utility model relates to sewage treatment dosing technical field, and disclose a gravity flow automatic dosing device, include: jar body, top plate, top plate fixed mounting in the top of jar body. The utility model discloses through jar body, drive motor and stirring subassembly etc. Structure mutual cooperation, when using, can utilize drive motor drive stirring subassembly in the driving gear, driven gear, spindle and stirring blade collaborative operation, the polymeric ferric sulfate etc. Pharmaceutical solution in jar body is fully and comprehensively stirred, in this way, effectively solved the problem that the solute precipitated in the jar body bottom because of the slow solution adding speed, long standing time when the pharmaceutical preparation and storage, avoided the precipitation to reduce the solution concentration uniformity, influence pharmaceutical dosing accuracy, and the situation that the precipitation accumulation reduces jar body effective volume, reduces the device operating efficiency, guaranteed the consistency of solution concentration, improved the overall operation efficiency of dosing device.

This invention provides a laboratory water tank for reducing the concentration of suspended solids in pharmaceutical solutions. The tank comprises a square tank with a downward-sloping central area. Within this recessed area, from top to bottom, are arranged the following: a sedimentation separation zone for preliminary solid-liquid separation of the liquid entering the tank; a filtration and adsorption zone connected to the lower end of the sedimentation separation zone for filtering and adsorbing the pre-separated liquid; and a purified liquid discharge zone connected to the lower end of the filtration and adsorption zone and connected to an external drainage pipe. This invention integrates sedimentation separation, multi-stage filtration, and adsorption functions, effectively intercepting and removing large particles of pharmaceutical residue and fine suspended solids from waste pharmaceutical solutions, while also effectively reducing dissolved organic matter, pigments, and odors, thus achieving effective pretreatment of laboratory waste pharmaceutical solutions at the source of discharge.

Provided are a multilayer film for a container, a container comprising the multilayer film, a method for manufacturing the container comprising the multilayer film, and a medical container containing a drug solution and containing the drug solution, the multilayer film being capable of suppressing oxidative deterioration of contents by oxygen remaining in the container or the contents and / or oxygen that permeates into the container, and also capable of suppressing oxidative deterioration of the contents by oxygen that remains in the container and / or the oxygen that permeates into the container, the container comprising the multilayer film, the method for manufacturing the container comprising the multilayer film, and the medical container containing the drug solution. As a result, it is possible to suppress adsorption of the contents on the film constituting the container, decrease in drug efficacy and adsorption of flavor substances, increase in the amount of the contents adsorbed on the film during the distillation step, uneven deformation of the film and occurrence of unevenness of the surface, and deformation of the container. A multilayer film for a container comprises: an outer film which is a transparent oxygen barrier film; an intermediate film which is a co-extruded film having an oxygen-absorbing layer; and an inner film which is a co-extruded film having a cyclic polyolefin layer containing a cyclic polyolefin, in which the intermediate film has a symmetrical laminated structure having a surface layer with the oxygen-absorbing layer as a core layer, and the inner film has a symmetrical laminated structure having a surface layer with the cyclic polyolefin layer as a core layer.

To provide a motility improver for male sperms.SOLUTION: The male sperm motility enhancing agent of the present invention contains nicotinamide mononucleotide (NMN), coenzyme Q10, and 5-aminolevulinic acid (5-ALA) as essential components. The agent for improving sperm motility can be used for infertility treatment of an adult male with reduced sperm motility and / or reduced sperm concentration, or for pregnancy activity (fertility) of an adult male. Another application is in the breeding of domesticated animals.SELECTED DRAWING: Figure 2

1. Name of the product in this design: Drug Liquid Proportioning Machine. 2. Purpose of this design: For use in the preparation of pharmaceutical solutions. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

Provided is a nozzle capable of suppressing splashing and dropping of two kinds of chemical solutions, and capable of achieving uniform mixed spraying and application to an appropriate range by means of sufficient atomization of the two kinds of chemical solutions. A nozzle for atomizing and spraying a first chemical solution and a second chemical solution for forming an adhesive for biological tissue by means of gas pressure is provided with: a first nozzle having a cylindrical first main body part through which the first chemical solution flows, and a first nozzle for spraying the first chemical solution, the first nozzle being provided at the tip of the first main body part; a second nozzle having a cylindrical second main body part through which a second chemical solution flows, and a second discharge port protruding from the tip of the second main body part toward the tip of the first main body part and discharging the second chemical solution; and a gas flow path having a gas discharge port for discharging a gas at least toward a space between the tip of the first main body part and the second discharge port. The end surface of the second discharge port is inclined so that an imaginary straight line connecting the most distal end and the rearmost end of the end surface approaches the second body portion from the distal end side toward the rear end side.

The invention relates to the technical field of biological medicine, in particular to a medicine solution composition, a preparation method thereof, a nasal spray and application. The medicine solution composition comprises a medicine active component, an osmotic pressure regulator, a pH regulator and water. The active pharmaceutical ingredient comprises ondansetron or a pharmaceutically acceptable salt of ondansetron. The medicine solution composition provided by the invention can be quickly absorbed into blood through nasal mucosa, reaches a peak within 5-10 minutes after being administered through nasal spray administration, is expected to take effect quickly, can help a patient to deal with nausea and vomiting caused by cytotoxic chemotherapy and radiotherapy in time and be used for preventing postoperative nausea and vomiting (PONV), and is good in stability.

To provide an agent for highly efficiently skipping an exon.SOLUTION: The present invention provides an antisense oligomer in which two or more unit oligomers targeting sequences that are not contiguous or overlapping with each other in the same exon are linked.SELECTED DRAWING: None

The invention discloses vacuum low-temperature evaporation equipment, and relates to the technical field of low-temperature evaporation. The device comprises a stock solution water tank used for storing and conveying liquid medicine; the raw water valve is used for opening or cutting off a liquid medicine conveying pipeline of the stock solution water tank and is connected with the stock solution water tank through a pipeline; and the filter is used for filtering particle impurities in the liquid medicine and is connected with the raw water valve through a pipeline. The core of the system is energy transfer and recovery of an evaporation internal circulation system, so that generation of secondary steam in internal circulation depends on heating of liquid medicine in the circulation process, energy is released after condensation recovery of the secondary steam, supplementary energy is provided for the circulation process, and an energy closed loop of evaporation-recovery-re-evaporation is formed by the secondary steam and the energy closed loop. Initial energy is provided through primary steam, energy circulation reuse is achieved through secondary steam, energy consumption is greatly reduced, it is guaranteed that feed liquid is evenly heated and continuously evaporated and concentrated, meanwhile, energy recovery reuse of the secondary steam is achieved, and stable operation of equipment is maintained.

[Problem] To provide: a nucleic acid molecule that is capable of inhibiting the expression of interleukin 33 (IL-33) or a gene encoding IL -33; a salt of the nucleic acid molecule; a solvate of the nucleic acid molecule or salt; a pharmaceutical composition characterized by containing the nucleic acid molecule, salt, or solvate as an active ingredient; and a prophylactic and / or therapeutic agent for diseases in which the involvement of IL-33 is implicated. [Solution] The present invention relates to: a nucleic acid molecule that is capable of inhibiting the expression of interleukin 33 (IL-33) or a gene encoding IL-33; and a pharmaceutical composition characterized by containing the nucleic acid molecule as an active ingredient.

To provide a therapeutic agent for myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) and fibromyalgia.SOLUTION: A therapeutic agent for a disease selected from myalgic encephalomyelitis / chronic fatigue syndrome and fibromyalgia, comprising 2-amino-2 - [2 - (4-heptyloxy-3-trifluoromethylphenyl) ethyl] propane-1, 3-diol or pharmaceutically acceptable salts thereof.SELECTED DRAWING: Figure 1

This utility model discloses a drug liquid anti-sedimentation storage and stirring device, relating to the technical field of storage devices. It includes a stirring tank, inside which a guide pipe is fixedly installed via a connecting rod. Several sets of openings of different heights are formed on the side wall of the guide pipe. A rotating shaft is rotatably installed inside the stirring tank, and a lifting screw is fixedly installed on the shaft within the guide pipe. A gap is left between the bottom of the guide pipe and the bottom of the stirring tank. A bottom rod is fixedly installed on the rotating shaft at the gap, contacting the bottom of the stirring tank. Side rods are fixedly installed on both sides of the bottom rod, contacting the side wall of the stirring tank. A motor is fixedly installed above the stirring tank, and the rotating shaft is connected to the motor drive end. A feed hopper is provided above the stirring tank, and a discharge pipe is connected to one side of the bottom of the stirring tank. This invention solves the technical problem of fixed height of the return pipe during drug liquid reflux in existing devices.

An aqueous pharmaceutical solution for the treatment of a central nervous system (CNS) disorder is provided, the solution comprising at least 5 mg / ml dissolved levodopa and a pH in the range of 3.0 to 8.5. The solution is provided by mixing: a) an aqueous stock solution comprising levodopa, the stock solution having a pH of less than 2.8 at 25°C, and b) an aqueous buffer solution for increasing the pH of the stock solution, the buffer solution having a pH of at least 4.0 at 25°C. The aqueous pharmaceutical solution is administered to a subject having a central nervous system (CNS) disorder shortly after mixing the aqueous stock solution and the aqueous buffer solution. Further, a kit for administering an aqueous pharmaceutical solution to a subject having a central nervous system (CNS) disorder is provided.

To provide a therapeutic agent for skin diseases having sufficient acne-treating effects without side effects.SOLUTION: The therapeutic agent for skin diseases contains micro / nano bubbles.SELECTED DRAWING: None

Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.